# A Study to Compare the Drug Levels of Atazanavir and Cobicistat Between the Coadministration of Age-Appropriate Mini-Tablet Formulations and the Coadministration of the Individual Reference Products in Healthy Adults Under Fed Conditions

> **NCT05236738** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 42 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** Atazanavir
- **DRUG:** Cobicistat
- **DRUG:** Atazanavir/Cobicistat Mini-tablet

## Key facts

- **NCT ID:** NCT05236738
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-13
- **Primary completion:** 2022-07-05
- **Final completion:** 2022-07-26
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2022-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05236738

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05236738, "A Study to Compare the Drug Levels of Atazanavir and Cobicistat Between the Coadministration of Age-Appropriate Mini-Tablet Formulations and the Coadministration of the Individual Reference Products in Healthy Adults Under Fed Conditions". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT05236738. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*